acute coronary syndromes
Conditions
Interventions
Test group:Aspirin (100mg, qd, orally) and ticagrelor (90mg, bid, orally) combined with rabeprazole (20mg/ day, qd, orally)
Control group:Aspirin (100mg, qd, orally) and ticagrelor (90mg, bid, orally)
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18-80 years, male or female; 2. Patients diagnosed as unstable angina or non-ST-segment elevation myocardial infarction for the first time, low and moderate risk ischemia with GRACE score < 140; 3. Dual antibody therapy with aspirin (100mg/day) and ticagrelor (180mg/day); 4. Agree to comply with all study procedures and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Active gastrointestinal bleeding or ulceration, or a history of gastrointestinal bleeding or ulceration within 24 months; 2.Long term oral anticoagulant; 3.Received related drugs that have influence on the experiment, including antibiotics, probiotics, drugs that inhibit gastric acid secretion and affect gastrointestinal flora in the past one month; 4.There are contraindications of magnetic controlled capsule endoscopy, such as intestinal obstruction, stenosis, diverticulum, fistula, etc., and a history of abdominal surgery to change the anatomical structure of the stomach and intestine, and refuse to undergo any abdominal surgery (once the capsule is incarcerated, surgical removal is required); 5. Combined with active cancer; 6. Severe renal insufficiency, eGFR 3 times upper limit; 10. Severe hypertension (> 180/100 mmHg) that has not been controlled; 11.Severe hemorrhoids (stage 3-4, according to American Society for Colorectal Surgery guidelines); 12.Planning pregnancy or surgery; 13.Conditions that affect the research process, such as dementia and mobility problems; 14.There are other ongoing clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the damage of stomach ;the damage of small intestine;gut microbiota;Clinical bleeding; | — |
Countries
China
Contacts
Public ContactJie Zhang
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed